Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Preferred Stock Liabilities (2024 - 2025)

Evommune (EVMN) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $257.0 million as the latest value for Q3 2025.

  • Quarterly Preferred Stock Liabilities rose 72.05% to $257.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $257.0 million through Sep 2025, up 72.05% year-over-year, with the annual reading at $191.8 million for FY2024, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q3 2025 was $257.0 million at Evommune, up from $191.8 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $257.0 million in Q3 2025, with the low at $149.4 million in Q3 2024.